ASCO Data Support Roche’s Grand Plan For Non-Stop Avastin Treatment
Executive Summary
After the loss of the breast cancer indication for Avastin, Roche looks to long-term treatment in colon cancer as growth driver. And fourth Phase III study of Avastin in ovarian cancer proves positive as the drug makes commercial headway in European markets where it is approved for this indication.
You may also be interested in...
How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value
With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.
Roche Experimenting With New Pricing Models In Oncology
Cancer drug prices are unsustainable and creative approaches are needed, Roche’s COO Daniel O’Day says. The firm’s moves into emerging markets are a lab for new methods, though the real test will come as the more expensive drugs are used in combination.
Roche Experimenting With New Pricing Models In Oncology
Cancer drug prices are unsustainable and creative approaches are needed, Roche’s O’Day says. The firm’s moves into emerging markets are a lab for new methods, he said, though the real test will come as the more expensive drugs are used in combination.